Physician profile
Paul Baughman
NPI 1902861230
$3,420.27
in general payments reported to CMS, 2019-2025
19 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $596 · 2021: $585 · 2022: $418 · 2023: $440 · 2024: $351 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,606.68 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.43 | 2020-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $290.82 | 2019-2024 | Trintellix |
| Lilly USA, LLC | $246.15 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Jazz Pharmaceuticals INC. | $222.40 | 2019-2022 | |
| Daiichi Sankyo INC. | $175.47 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $84.97 | 2022-2024 | Contrave, Onzetra Xsail |
| Corcept Therapeutics | $73.13 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $66.64 | 2020-2021 | |
| Eisai INC. | $59.19 | 2019 | |
| Intra-Sana Laboratories | $57.26 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Optinose US, INC. | $39.40 | 2023 | |
| Ironshore Pharmaceuticals INC. | $39.39 | 2019-2020 | |
| Neos Therapeutics, Lp | $31.24 | 2019 | |
| Xeris Pharmaceuticals, INC. | $30.57 | 2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.98 | 2019-2021 | |
| Inspire Medical Systems, INC. | $19.25 | 2025 | Inspire |
| Rhythm Pharmaceuticals, INC. | $17.13 | 2023 | Imcivree |
| Sanofi-Aventis U.S. LLC | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Baughman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.